Nykode Therapeutics announced H1 financial results on August 23rd.
- total revenue and other income of USD 8.4 million, compared to USD 4.4 million for the second quarter of 2022.
- total operating expenses of USD 35.0 million, compared to USD 23.3 million for the second quarter of 2022.
- Net loss of USD 19.6 million, compared to a net loss of USD 15.6 million for the second quarter of 2022.
- Strong cash position of USD 173.6 million as of June 30, 2023